Celularity attracts big bucks and names with vision for longer life
In biotech, investors are used to hearing big pledges from start-ups about their capacity to meet needs and cure diseases, but even in this optimistic field, some of the goals set by a new US company are unusually ambitious.
The formation of Celularity, set up by stem cell pioneer Robert Hariri, has been announced with $250 million in funding from backers including biotech companies Celgene (Nasdaq: CELG), United Therapeutics (Nasdaq: UTHR) and Sorrento Therapeutics (Nasdaq: SRNE), as well as Human Longevity, the genomic-based, health intelligence venture.
"My goal is to make it so the next generation grows up in a world where cancer is managed just like the common cold, and the body's natural regenerative engine remains empowered throughout our lives"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze